Neuromyelitis Optica Spectrum Disorder Pipeline Shows 10+ Active Therapies in Development

Over 10 pharmaceutical companies are actively developing more than 12 pipeline therapies for Neuromyelitis Optica Spectrum Disorder (NMOSD), according to a comprehensive pipeline analysis. The pipeline includes clinical and nonclinical stage products assessed by product type, stage, route of administration, and molecule type.

On February 13, 2026, Hoffmann-La Roche announced a phase III study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.

Leading companies working in the NMOSD space include Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co. Ltd, Shanghai Xiniao Biotech Co., Ltd. and others. Promising therapies in development include Ravulizumab, B001, Eculizumab, Inebilizumab, MIL62, satralizumab, azathioprine (AZA), NPB-01, JYP0061 and others.

BAT4406F, developed by Bio-Thera Solutions, is an investigational ADCC-enhanced anti-CD20 mAb candidate in clinical development for the treatment of autoimmune diseases. BAT4406F is currently being evaluated in NMOSD, an orphan indication with an estimated prevalence of 0.5 to 10 per 100,000. BAT4406 is a type I glyco-engineered mAb that binds specifically to CD20 on B-cells, kills the B-cells by CDC, and enhances ADCC effect. The drug is currently in Phase III stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder.

B001, developed by Shanghai Jiaolian Drug Research and Development Co., Ltd, is a recombinant humanized anti-CD20 monoclonal antibody. It works by targeting CD20 on B cells and triggering antibody-dependent cellular cytotoxicity (ADCC) to deplete autoreactive B cells, a mechanism aligned with current NMOSD treatment goals. Designed for intravenous administration, B001 aims to reduce disease relapses.

Neuromyelitis Optica Spectrum Disorder is a rare, severe autoimmune disease of the central nervous system in which the body's immune system mistakenly attacks healthy cells in the optic nerves and spinal cord. This condition often leads to episodes of optic neuritis (causing eye pain and vision loss) and transverse myelitis (causing weakness, paralysis, sensory loss, and bladder or bowel dysfunction). Unlike multiple sclerosis, NMOSD is commonly associated with antibodies against aquaporin-4 (AQP4-IgG), which target water channel proteins on astrocytes, leading to inflammation and nerve damage.

B cells have been implicated in the pathogenesis of a number of autoimmune diseases, including the CNS disorders, multiple sclerosis (MS) and NMOSD. Depletion of B-cells could provide meaningful relief for these autoimmune diseases. NMOSD is an autoimmune inflammatory disorder of the central nervous system (CNS) with preferential localization to the optic nerve, spinal cord and brain stem. Patients typically experience bouts of vision loss or blindness, attacks of myelitis with often severe motor impairment including loss of ambulation, sensory disturbances, bowel/bladder dysfunction, and brainstem attacks with characteristic episodes of intractable nausea, vomiting and hiccups.